chromatography (Pierce, Rockford, Ill.), and their concentrations were determined by enzyme-linked immunosorbent assay.
J774.16 cells were maintained and stimulated as described previously (31) ; cells were plated at 0.9 ϫ 10 4 to 2 ϫ 10 4 /well in 96-well tissue culture plates (Falcon, Lincoln Park, N.J.) and grown for 1 day. J774.16 cells were then subjected to experimental conditions, and after 3 days, NO production was inferred by determination of nitrite levels with the Griess reagent (31) .
RNA was isolated from confluent plates (Falcon) of J774.16 cells with the TRIzol reagent and protocol (Molecular Research Center, Inc., Cincinnati, Ohio). cDNA was generated with avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim) and random hexanucleotides (Boehringer Mannheim). Inducible NO synthase (iNOS) and hypoxanthine phosphoribosyltransferase (HPRT) mRNAs were amplified by PCR with specific oligonucleotides with the AmpliTaq DNA polymerase kit (Perkin-Elmer Cetus, Branchburg, N.J.). Oligonucleotides were synthesized at the Albert Einstein College of Medicine DNA synthesis facility on the basis of the following published sequences: iNOS, 5Ј-TTCCGAAGTTTCTGG CAGCA (sense), 5Ј-TGTCAGAGCCTCGTGGCTTT (antisense) (29) ; HPRT, 5Ј-GTTGGATACAGGCCAGACTTTGT TG (sense), 5Ј-GAGGGTAGGCTGGCCTATGGCT (antisense) (39) . PCR products were fractionated on a 1.5% agarose gel and visualized with ethidium bromide.
Since endotoxin enhances nitrite production by IFN-␥-primed murine macrophages, great care was taken to prevent contamination, including the use of endotoxin-free pipette tips (Costar, Cambridge, Mass.), reagents, and labware. All work was carried out in a biohazard hood under sterile conditions. Endotoxin levels were measured with the Limulus amebocyte lysate assay (BioWhittaker), with AmB (BioWhittaker) at Ͻ0.3 ng/ml and MAbs and CNPS solutions at Ͻ0.15 ng/ml. The data shown represent the means and standard deviations for experiments in duplicate. Pairwise comparisons were done with Student's t test.
AmB was added to J774.16 cells in twofold dilutions (10 to 0.02 g/ml). In the absence of IFN-␥, AmB had no effect on J774.16 nitrite production (Fig. 1) . In the presence of IFN-␥ (125 U/ml), AmB augmented J774.16 nitrite production in a dose-dependent manner, with the maximal effect at 2.5 g/ml. At AmB concentrations greater than 2.5 g/ml, nitrite levels declined, although they remained higher than those obtained with IFN-␥ alone (Fig. 1) , and microscopic examination re-vealed fewer macrophages, consistent with reports of AmB cytotoxicity at concentrations Ͼ5 g/ml (8, 36) .
To examine the possibility of endotoxin contamination, J774.16 cells were incubated with polymyxin B sulfate (1 g/ ml) and twofold dilutions of AmB (20 to 0.02 g/ml). In the absence of IFN-␥, AmB had no effect on J774.16 nitrite production (data not shown). In the presence of IFN-␥ (125 U/ ml), AmB significantly increased nitrite production despite the presence of polymyxin B, with maximal nitrite production occurring at 2.5 g/ml (Fig. 2) .
To determine whether CNPS affects AmB enhancement of nitrite synthesis, J774.16 cells were incubated with AmB (10 to 0.01 g/ml) and CNPS serotype B (CNPS-B) or CNPS-D (10 g/ml). A second set of J774.16 cultures received MAb 2D10 (5 g/ml) in addition to the components mentioned above. In the absence of IFN-␥, the addition of CNPS, MAb, or CNPS plus MAb, had no effect on nitrite production, with or without AmB (data not shown). With IFN-␥ (125 U/ml), CNPS alone did not alter nitrite levels, but CNPS plus antibody enhanced J774.16 nitrite production, as expected (31), and AmB further increased nitrite synthesis in these cultures, whether with CNPS-B ( production by J774.16 cells, either with or without 2.5 g of AmB per ml (data not shown).
J774.16 cultures were treated with medium (control), IFN-␥ (125 U/ml), AmB (2.5 g/ml), or IFN-␥ plus AmB for 18 h. AmB plus IFN-␥ resulted in a nitrite level approximately 2.4 times greater than that induced by IFN-␥ alone. Expression of iNOS mRNA was documented by reverse transcription-PCR (Fig. 4) .
Despite its widespread use and clinical importance as an antifungal drug, the mechanism of AmB action in vivo is uncertain (5). AmB is unable to eradicate C. neoformans infection in the setting of profound immunosuppression, and yet it can cure most cases of cryptococcosis in the absence of human immunodeficiency virus infection (10) . Others have observed that the in vitro anticryptococcal effect of AmB-and IFN-␥-treated murine macrophages depends upon NO (43) . Our findings add support to the hypothesis that some of the in vivo antifungal effects of AmB are the result of macrophage stimulation and NO production. We observed that AmB increases J774.16 nitrite production at drug concentrations comparable to levels achieved in serum and tissue during AmB therapy (37) . It is unlikely that our results are due to endotoxin contamination, given that careful precautions were taken and the fact that the nitrite-augmenting effects of AmB were retained in the presence of the endotoxin antagonist polymyxin B.
Although the role of NO in human cryptococcosis is unknown, there are now considerable data demonstrating that various human cell types produce NO in an inducible manner (30, 52) . Human alveolar macrophages express iNOS in the presence of Mycobacterium tuberculosis and Mycobacterium avium (14, 35) , and human astrocytes have been demonstrated to produce sufficient NO to kill cryptococci in vitro (27) .
Cytokine-induced NO is produced from L-arginine by iNOS. In murine macrophages, exogenous administration of IFN-␥ and the subsequent TNF-␣ secretion lead to expression of this enzyme (Fig. 5) . In vitro, AmB-induced TNF-␣ release is partially responsible for the increase in macrophage NO (43) . AmB also induces TNF-␣ in mice (44, 50) ; therefore, AmB may augment NO synthesis in vivo. NO production in mice does correlate with increased resistance to C. neoformans (28) .
Our results suggest that AmB is a powerful macrophage activator, since it is able to increase nitrite from cells stimulated with a maximal amount of IFN-␥. Had we used submaximal concentrations of cytokine, we might have observed AmB having an even greater effect. The fact that AmB can increase nitrite production in the presence of immune complexes and a maximally stimulating concentration of IFN-␥ suggests that AmB, antigen-antibody complexes, and IFN-␥ utilize different signalling pathways to increase macrophage NO, although they may all ultimately act through increased expression of macrophage cytokines such as TNF-␣.
AmB can augment J774.16 nitrite production in the presence of CNPS. Cryptococcal infections are often characterized by a heavy burden of CNPS in tissues, serum, and cerebrospinal fluid (15, 17, 25, 26, 38) , and CNPS is a virulence factor (6, 16, 23) that mediates potentially deleterious effects on host leukocytes, including inhibition of TNF-␣ production by human monocytes (4, 7, 24, 46, 47) . Considering that TNF-␣ is utilized for the induction of murine macrophage iNOS (11) and that CNPS has pleiotropic effects on macrophages, it is important that the effect of AmB was retained in the presence of CNPS.
Two anticapsular antibody-based strategies are being considered for treatment of C. neoformans infection: vaccination with an immunogenic conjugate vaccine (9) and passive anticapsular antibody administration (51) . In this study, we have duplicated our previous results showing that anticapsular MAbs plus CNPS enhance J774.16 nitrite synthesis in the presence of a maximal amount of IFN-␥. This result is dependent upon immune complex formation, because irrelevant isotypematched antibodies have no effect on nitrite levels (31). Here we report that AmB increases the level of J774.16 nitrite production above that obtained with CNPS-antibody complexes in the presence of a maximal amount of IFN-␥. We speculate that the combination of AmB plus pathogen-specific antibody may lead to increased macrophage NO in vivo. Passive administration of anticapsular MAbs in conjunction with AmB improves survival in mice infected with C. neoformans and is more efficacious than either agent alone (12, 18, 33) .
The combination of AmB and IFN-␥ has been shown to be synergistic against C. neoformans in mice (22) . We observed that AmB augments IFN-␥-induced murine macrophage nitrite, but does not affect nitrite production on its own. In the absence of IFN-␥, live or killed C. neoformans cells in combination with AmB also did not enhance J774.16 nitrite production, whether or not the yeasts were opsonized. This dependence of AmB on IFN-␥ has been documented by others (21, 43) and allows one to speculate on a potential mechanism for the reduced efficacy of AmB in patients with AIDS or other T-cell deficiencies. CD4 ϩ T-cell lymphopenia or dysfunction could translate into suboptimal IFN-␥ priming for macrophage stimulation, consistent with the observation that AmB is significantly less effective for treatment of C. neoformans in Tcell-deficient mice (20) .
We speculate that T-cell-deficient patients with cryptococcosis may benefit from treatment with IFN-␥ and/or anticapsular antibodies. The development of adjunctive immunotherapy appears to be a rational step, considering that serious cryptococcal infections tend to occur in immunocompromised hosts and that the efficacy of antifungal chemotherapy remains unsatisfactory in these patients.
